NCT06546384View on ClinicalTrials.gov

GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease

NANot yet recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions
AdiposityFatty LiverAlcohol Use Disorder
Interventions
DRUG

Semaglutide

"Treatment with semaglutide, following standard clinical practice as per below schedule:~Week 1-4: Injected dose of 0,25 mg i.d. Week 5-8: Injected dose of 0,5 mg i.d. Week 9-12: Injected dose of 1,0 mg i.d. Week 13-16: Injected dose of 1,7 mg i.d. After week 16: Injected dose of 2,4 mg i.d."

BEHAVIORAL

Weight reduction recommendations (nutritional and exercise)

Participants will receive nutritional and exercise recommendations and 2 telephone consultations

Trial Locations (1)

3010

University Hospital Bern, Bern

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT06546384 - GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | Biotech Hunter | Biotech Hunter